AstraZeneca PLC (AZN)
| Market Cap | 241.43B |
| Revenue (ttm) | 56.50B |
| Net Income (ttm) | 8.30B |
| Shares Out | 1.55B |
| EPS (ttm) | 5.31 |
| PE Ratio | 14.64 |
| Forward PE | 16.06 |
| Dividend | $1.54 (1.98%) |
| Ex-Dividend Date | Aug 8, 2025 |
| Volume | 4,658,789 |
| Open | 77.19 |
| Previous Close | 77.56 |
| Day's Range | 77.07 - 78.08 |
| 52-Week Range | 61.24 - 82.41 |
| Beta | 0.17 |
| Analysts | Strong Buy |
| Price Target | n/a |
| Earnings Date | Nov 11, 2025 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial StatementsNews
AstraZeneca's Fasenra Falls Short In Smoker's Lung Trial
AstraZeneca Plc AZN released on Wednesday topline data from RESOLUTE Phase 3 trial of Fasenra (benralizumab).
SAPHNELO self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from a pre-specified interim analysis of the Phase III TULIP-SC trial in patients with systemic lupus erythematosus (SLE) showed that the...
AstraZeneca's asthma drug fails main goal of COPD study
AstraZeneca said on Wednesday that its asthma drug Fasenra failed the main goal of a late-stage study in patients with chronic obstructive pulmonary disease (COPD).
AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit
The U.K.-based AstraZeneca Plc AZN paused a planned 200 million pounds ($271.26 million) investment in its Cambridge research site.
AstraZeneca shares down 3% after rating cut, UK investment pause
AstraZeneca shares fell as much as 3.4% on Monday, their steepest drop since May, after Handelsbanken cut its rating on the drugmaker and Reuters reported the company had paused a major investment in ...
AstraZeneca Pauses Plans for $271 Million Expansion of U.K. Site
The company has shelved plans for a research facility in Cambridge, a move that follows the drugmaker in January scrapping an investment in Liverpool.
AstraZeneca pauses £200mn Cambridge investment amid UK pharma uncertainty
AstraZeneca has become the latest major drugmaker to scale back investment in the United Kingdom, pausing a planned £200 million ($271 million) expansion of its Cambridge research site. The move, whic...
Exclusive: AstraZeneca pauses $270 million investment in Britain
Britain's biggest company AstraZeneca has paused a planned 200 million pound ($271.26 million) investment in its Cambridge research site, a spokesperson said, the latest drugmaker to retreat from Brit...
US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says
The impact of U.S. President Donald Trump's plan to levy import duties on pharmaceutical products and his push to lower drug prices are likely to be manageable for big U.S. and European drugmakers, ac...
Global drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
Final Trades: AstraZeneca, Corning, the IBIT and the SPHD
The Investment Committee give you their top stocks to watch for the second half.
AstraZeneca: Buy This Pharma Star Now For Upside Potential
Since last month, AstraZeneca's shares have trounced the S&P 500 index. The drugmaker has an impressive drug portfolio and a deep pipeline, which should continue to drive core EPS growth for the fores...
AstraZeneca to seek approval for blood pressure drug by year-end
AstraZeneca plans to file for regulatory approval of its experimental blood pressure treatment before the end of the year, a senior company executive said, about a product seen as key to the drugmaker...
Polaris Pharmacy Services Named Exclusive U.S. Distributor of AstraZeneca's FluMist® Home Service—The World's First At-Home Nasal Spray Flu Vaccine
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Polaris Pharmacy Services, a leading provider of long-term care and specialty pharmacy solutions, has been selected as the exclusive U.S. distributor for FluMis...
The Healthcare Businesswomen's Association (HBA) Honors AstraZeneca and Viseven with 2025 ACE Awards for Workforce Innovation and Global Impact
The HBA's ACE Awards spotlight bold, people-first programs that are transforming how the industry develops, engages, and empowers its workforce. FAIRFIELD, N.J.
AstraZeneca: Great Portfolio, But Not A Great Price
AstraZeneca PLC boasts strong 2024 results with $54B revenue and 14 blockbuster drugs, driven by robust growth in oncology and rare disease franchises. Key products like Farxiga, Tagrisso, and Ultomir...
SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes
BOSTON and ROLLE, Switzerland , Aug. 5, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a...
Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges
Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
European drugmakers fall after Trump raises stakes over US drug price cuts
Shares of European drugmakers slipped on Friday after U.S. President Donald Trump sent letters to major pharmaceutical firms to cut drug prices in the United States, months after signing a sweeping ex...
Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says
President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to “end the free ride of Ame...
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.
President Donald Trump on Thursday said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.
Trump pressures 17 pharma CEOs to cut US drug prices
U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House sa...